source
- Dimerix buys a kidney injury drug; Arpeggio appears to be winding downPlus, news about Takeda, Novartis and Regenxbio. 🤝 Mission sells kidney injury drug to Dimerix: Dimerix will pay $5 million upfront for Mission’s Phase 2-ready candidate for acute kidney injury, k…Endpoints · 13d ago↗ source
- STAT+: The end for GSK’s chronic cough treatmentSonothera's ultrasound gene therapy delivery, a new Alzheimer's drug controversy, and more biotech news from The ReadoutSTAT · 13d ago↗ source
- Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugsLast summer, zero biotechs made it onto the public markets as the industry weathered a seven-month dry spell for initial share sales. This time around, it's a summer IPO party as six